FDA takes numerous actions on dietary supplements to protect public health.
FDA works with industry and our state partners to publish press releases and other public notices about recalls that may potentially present a significant or serious risk to the consumer or user of the product. Not all recalls have press releases or are posted on this page. See additional information on recalls.
FDA issues Warning Letters to let companies know that they have violated the laws we enforce and to tell them what corrective action they need to take. See additional information on warning letters.
- FDA Issues Warning Letters to Companies Selling Dietary Supplements that Claim to Treat Cardiovascular Disease
- FDA Releases Draft Guidance on NDI Enforcement Discretion
- FDA Sends Warning Letters to Multiple Companies for Illegally Selling Adulterated Dietary Supplements
- FDA and FTC Send Warning Letters to 10 Companies for Illegally Selling Dietary Supplements Claiming to Treat Diabetes
- FDA and FTC Send Warning Letters to Five Companies for Illegally Selling Dietary Supplements Claiming to Treat Infertility
- FDA Acts on Dietary Supplements Containing DMHA and Phenibut
- FDA Implements New Dietary Supplement Ingredient Advisory List
- FDA Announcing Public Meeting to Discuss Responsible Innovation in Dietary Supplements
New Efforts to Strengthen Regulation of Dietary Supplements